Human Liver Models Market Size, Trends and Growth Analysis by 2027

The human liver models market is anticipated to achieve a valuation of US$ 508.26 million by the year 2028, rising from US$ 233.90 million in 2021. This growth trajectory indicates a compound annual growth rate (CAGR) of 11.7% from 2021 through 2028.

The primary drivers behind this market expansion include the increasing incidence of liver-related diseases and a heightened emphasis on creating alternatives to traditional animal testing models. Additionally, advancements in organ printing technology are expected to significantly contribute to the market's growth during the forecast period. Nevertheless, challenges such as the high costs associated with human liver models and difficulties in integrating these models into current workflows are acting as barriers to market progress.

The impact of the COVID-19 pandemic in North America has been profound, particularly in the United States. The surge in COVID-19 cases has led to substantial modifications in healthcare practices nationwide. These pandemic-related challenges have adversely affected liver transplantation procedures in the region, posing a potential risk to the human liver models market in the coming years.

The human liver models market is categorized by type into several segments: liver organoids, liver-on-a-chip, 2D models, 3D bioprinting, and others. Among these, the liver organoids segment currently holds the largest market share. However, the liver-on-a-chip segment is projected to experience the highest CAGR during the forecast period.

When examining the market by application, it is divided into educational, drug discovery, and other categories. The drug discovery segment commands the largest share of the market, while the educational segment is expected to witness the most significant growth rate during the forecast period.

In terms of end users, the market is segmented into research institutes, pharmaceutical and biotechnology companies, and others. The pharmaceutical and biotechnology sector is the dominant player in the market. However, the research institutes segment is forecasted to achieve the highest CAGR throughout the forecast period.

To compile the report on the human liver models market, various primary and secondary sources were consulted, including organizations such as the World Health Organization (WHO), the European Federation of Pharmaceutical Industry Associations, and the Pharmaceutical Research and Manufacturers of America.

In summary, the human liver models market is poised for substantial growth driven by the rising prevalence of liver diseases and the shift towards alternative testing methods. While challenges remain, particularly in terms of costs and integration into existing systems, the advancements in technology and the increasing focus on research and development in this area are likely to propel the market forward. Stakeholders in the pharmaceutical and biotechnology sectors, as well as research institutions, will play a crucial role in shaping the future of this market.